Literature DB >> 19027750

Endothelial dysfunction in adiponectin deficiency and its mechanisms involved.

Yu Cao1, Ling Tao, Yuexing Yuan, Xiangying Jiao, Wayne Bond Lau, Yajing Wang, Theodore Christopher, Bernard Lopez, Lawrence Chan, Barry Goldstein, Xin L Ma.   

Abstract

Endothelial dysfunction is the earliest pathologic alteration in diabetic vascular injury and plays a critical role in the development of atherosclerosis. Plasma levels of adiponectin (APN), a novel vasculoprotective adipocytokine, are significantly reduced in diabetic patients, but its relationship with endothelial dysfunction remains unclear. The present study aims to determine whether APN deficiency may cause endothelial dysfunction and to investigate the involved mechanisms. Vascular rings were made from the aortic vessels of wild type (WT) or APN knockout (APN(-/-)) mice. Endothelial function, total NO production, eNOS expression/phosphorylation, superoxide production, and peroxynitrite formation were determined. ACh and acidified NaNO2 (endothelial dependent and independent vasodilators, respectively) caused similar concentration-dependent vasorelaxation in WT vascular rings. APN(-/-) rings had a normal response to acidified NaNO2, but a markedly reduced response to ACh (>50% reduction vs. WT, P<0.01). Both superoxide and peroxynitrite production were increased in APN(-/-) vessels (P<0.01 vs. WT). Pretreatment with superoxide scavenger Tiron significantly, but incompletely restored vascular vasodilatory response to ACh. In APN(-/-) vessels, eNOS expression was normal, but NO production and eNOS phosphorylation was significantly reduced (P<0.01 vs. WT). Treatment of APN(-/-) mice in vivo with the globular domain of adiponectin reduced aortic superoxide production, increased eNOS phosphorylation, and normalized vasodilatory response to ACh. Increased NO inactivation combined with decreased basal NO production contributes to endothelial dysfunction development when there is a paucity of APN production. Interventions directed towards increasing plasma APN levels may improve endothelial function, and reduce cardiovascular complications suffered by diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027750      PMCID: PMC2671019          DOI: 10.1016/j.yjmcc.2008.10.014

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  35 in total

1.  Gene transfer of endothelial nitric oxide synthase improves relaxation of carotid arteries from diabetic rabbits.

Authors:  D D Lund; F M Faraci; F J Miller; D D Heistad
Journal:  Circulation       Date:  2000-03-07       Impact factor: 29.690

2.  Nitric oxide signaling comes of age: 20 years and thriving.

Authors:  Santiago Lamas; Charles J Lowenstein; Thomas Michel
Journal:  Cardiovasc Res       Date:  2007-06-02       Impact factor: 10.787

3.  Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany.

Authors:  Wolfgang Koenig; Natalie Khuseyinova; Jens Baumert; Christa Meisinger; Hannelore Löwel
Journal:  J Am Coll Cardiol       Date:  2006-09-12       Impact factor: 24.094

4.  Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.

Authors:  John B Buse; Henry N Ginsberg; George L Bakris; Nathaniel G Clark; Fernando Costa; Robert Eckel; Vivian Fonseca; Hertzel C Gerstein; Scott Grundy; Richard W Nesto; Michael P Pignone; Jorge Plutzky; Daniel Porte; Rita Redberg; Kimberly F Stitzel; Neil J Stone
Journal:  Circulation       Date:  2006-12-27       Impact factor: 29.690

5.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

Authors:  K Hotta; T Funahashi; Y Arita; M Takahashi; M Matsuda; Y Okamoto; H Iwahashi; H Kuriyama; N Ouchi; K Maeda; M Nishida; S Kihara; N Sakai; T Nakajima; K Hasegawa; M Muraguchi; Y Ohmoto; T Nakamura; S Yamashita; T Hanafusa; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-06       Impact factor: 8.311

6.  Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity.

Authors:  Rong Li; Wen-Qing Wang; Haifeng Zhang; Xinchung Yang; Qian Fan; Theodore A Christopher; Bernard L Lopez; Ling Tao; Barry J Goldstein; Feng Gao; Xin L Ma
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-09-25       Impact factor: 4.310

Review 7.  Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention.

Authors:  Weidong Zhu; Kenneth K Y Cheng; Paul M Vanhoutte; Karen S L Lam; Aimin Xu
Journal:  Clin Sci (Lond)       Date:  2008-03       Impact factor: 6.124

8.  Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction.

Authors:  Abdulrahman K Doughan; David G Harrison; Sergey I Dikalov
Journal:  Circ Res       Date:  2007-12-20       Impact factor: 17.367

9.  Adiponectin protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt, and nitric oxide.

Authors:  Adrian T Gonon; Ulrika Widegren; Aliaksandr Bulhak; Firoozeh Salehzadeh; Jonas Persson; Per-Ove Sjöquist; John Pernow
Journal:  Cardiovasc Res       Date:  2008-01-25       Impact factor: 10.787

Review 10.  Adipokines and vascular disease in diabetes.

Authors:  Barry J Goldstein; Rosario Scalia
Journal:  Curr Diab Rep       Date:  2007-02       Impact factor: 5.430

View more
  47 in total

1.  Adipose tissue as regulator of vascular tone.

Authors:  Charlotte Boydens; Nele Maenhaut; Bart Pauwels; Kelly Decaluwé; Johan Van de Voorde
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

2.  Gender differences in adiponectin modulation of cardiac remodeling in mice deficient in endothelial nitric oxide synthase.

Authors:  Jorge L Durand; Andrea R Nawrocki; Philipp E Scherer; Linda A Jelicks
Journal:  J Cell Biochem       Date:  2012-10       Impact factor: 4.429

Review 3.  Systemic adiponectin malfunction as a risk factor for cardiovascular disease.

Authors:  Wayne Bond Lau; Ling Tao; Yajing Wang; Rong Li; Xin L Ma
Journal:  Antioxid Redox Signal       Date:  2011-04-20       Impact factor: 8.401

Review 4.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

Review 5.  Cardiovascular response to thermoregulatory challenges.

Authors:  Cuiqing Liu; Zubin Yavar; Qinghua Sun
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-02       Impact factor: 4.733

Review 6.  Modulation of Vascular Reactivity by Perivascular Adipose Tissue (PVAT).

Authors:  Claudia Agabiti-Rosei; Anna Paini; Carolina De Ciuceis; Sarah Withers; Adam Greenstein; Anthony M Heagerty; Damiano Rizzoni
Journal:  Curr Hypertens Rep       Date:  2018-05-07       Impact factor: 5.369

7.  Coronary and aortic endothelial function affected by feedback between adiponectin and tumor necrosis factor α in type 2 diabetic mice.

Authors:  Hanrui Zhang; Yoonjung Park; Cuihua Zhang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-09-02       Impact factor: 8.311

8.  Autologous fat transplants to deliver glitazone and adiponectin for vasculoprotection.

Authors:  William G Sanders; Huan Li; Ilya Zhuplatov; Yuxia He; Seong-Eun Kim; Alfred K Cheung; Jayant Agarwal; Christi M Terry
Journal:  J Control Release       Date:  2017-09-01       Impact factor: 9.776

9.  Obesity, diabetes and survival in maintenance hemodialysis patients.

Authors:  Serpil M Deger; Charles D Ellis; Ahuia Bian; Ayumi Shintani; T Alp Ikizler; Adriana M Hung
Journal:  Ren Fail       Date:  2014-01-28       Impact factor: 2.606

Review 10.  Adipokines and blood pressure control.

Authors:  Frederique Yiannikouris; Manisha Gupte; Kelly Putnam; Lisa Cassis
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-03       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.